Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Current Deferred Revenue (2025)

Organogenesis Holdings (ORGO) has 1 years of Current Deferred Revenue data on record, last reported at $3.9 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, changed N/A, while the annual FY2025 figure was $3.9 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $3.9 million in Q4 2025 per ORGO's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.9 million in Q4 2025 and bottomed at $1.5 million in Q3 2025.